Abstract
Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Central Nervous System Agents in Medicinal Chemistry
Title: Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Volume: 11 Issue: 2
Author(s): Lei Lv, Yu-Ping Tang, Xiang Han, Xin Wang and Qiang Dong
Affiliation:
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Abstract: Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Export Options
About this article
Cite this article as:
Lv Lei, Tang Yu-Ping, Han Xiang, Wang Xin and Dong Qiang, Therapeutic Application of Histone Deacetylase Inhibitors for Stroke, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152411796011330
DOI https://dx.doi.org/10.2174/187152411796011330 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Synthesis and Biological Evaluation of Novel Bioisosteric Analogues of Dimebon™
Letters in Drug Design & Discovery Amyloid Beta Peptide, 4-Hydroxynonenal and Apoptosis
Current Alzheimer Research Repetitive Transcranial Magnetic Stimulation for ALS
CNS & Neurological Disorders - Drug Targets Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Current Alzheimer Research A Comparative Study Among Various Statistical Tests Using Microarray Gene Expression Data
Current Bioinformatics Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience Conference Report
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships Part IV)
Current Physical Chemistry Autophagy to the Rescue
Current Neurovascular Research The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Plant Phenylpropanoids as Emerging Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Prolyl Oligopeptidase Structure and Dynamics
CNS & Neurological Disorders - Drug Targets N-Aryl-5-aminopyrazole: A Versatile Architecture in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Differential Effects of Nicotine Exposure on the Hippocampus Across Lifespan
Current Neuropharmacology Low Density Lipoprotein Receptor-Related Proteins (LRPs), Alzheimers and Cognition
Current Drug Targets - CNS & Neurological Disorders Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design